Alogliptin

Dipeptidyl Peptidase 4 Inhibitor — ALIMENTARY TRACT AND METABOLISM

Key facts

Alogliptin is an onp drug in the Dipeptidyl Peptidase 4 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Dipeptidyl Peptidase 4 Inhibitors. DrugCentral lists 2 molecular targets, including DPP4 and Dpp4. Recorded indications include Diabetes mellitus type 2.

• Approval status: onp (first approved 2013 by the FDA).
• Drug class: Dipeptidyl Peptidase 4 Inhibitor.
• Mechanism of action: Dipeptidyl Peptidase 4 Inhibitors.
• Molecular targets: DPP4 and Dpp4 (2 listed in DrugCentral).
• Indications: Diabetes mellitus type 2.
• ATC code: A10BD09 (Combinations of oral blood glucose lowering drugs).
• Molecular formula: C18H21N5O2; molecular weight 339.40 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Diabetes mellitus type 2

Mechanism & targets

• Mechanism of action (MoA): Dipeptidyl Peptidase 4 Inhibitors
• Established pharmacologic class: Dipeptidyl Peptidase 4 Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Dipeptidyl peptidase 4	DPP4	inhibitor	IC50 9.00
Dipeptidyl peptidase 4	Dpp4	unknown	IC50 8.07

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2013-01-25	FDA	—	TAKEDA PHARMS USA

ATC classification

ATC code	Therapeutic hierarchy
A10BD09	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs
A10BD13	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs
A10BH04	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pemphigoid	368.4
Cerebral infarction	141.0
Pancreatitis	99.0
Pancreatitis acute	90.2
Interstitial lung disease	85.3
Diabetic ketoacidosis	83.0
Lactic acidosis	62.9
Euglycaemic diabetic ketoacidosis	59.0
Pancreatic carcinoma	55.7
Hypoglycaemia	55.6
Gastric cancer	49.2
Tonsil cancer	48.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Alogliptin is on its molecule page.

• Molecular formula: C₁₈H₂₁N₅O₂
• Molecular weight: 339.40 g/mol
• CAS number: —
• InChIKey: ZSBOMTDTBDDKMP-OAHLLOKOSA-N
• PubChem CID: 11450633

CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Alogliptin used for?

DrugCentral lists the following indications for Alogliptin: Diabetes mellitus type 2.

How does Alogliptin work?

Alogliptin is classified as Dipeptidyl Peptidase 4 Inhibitors; its molecular targets in DrugCentral include DPP4 (inhibitor) and Dpp4.

When was Alogliptin first approved?

Alogliptin was first approved by the FDA in 2013.

What drug class does Alogliptin belong to?

Alogliptin is in the Dipeptidyl Peptidase 4 Inhibitor class.

What is the chemical formula of Alogliptin?

Alogliptin has the molecular formula C18H21N5O2 and a molecular weight of 339.40 g/mol.

Sources

• DrugCentral drug card 4340 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL227529 — compound record and bioactivity
• PubChem CID 11450633 — chemical identifiers
• DrugBank DB06203 — drug record
• FDA UNII JHC049LO86 — substance identity
• DailyMed: FDA labels for Alogliptin — current prescribing information (label search)
• UniProt P27487 (DPP4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.